Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Champ Baker

Sports Medicine Columbus, GA Medical Doctor

NPI 1912128448 CMS profile 177257

6262 Veterans Pkwy, Columbus, GA 31909

Open in the dashboard

General payments

$12,452

64 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Champ Baker of Columbus, GA is reported in the CMS Open Payments database as having received $12,452 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,006 21
2024 General $634 8
2023 General $5,375 22
2022 General $1,286 6
2021 General $115 5
2019 General $36 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Champ Baker
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Champ Baker were reported at $5,006. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Champ Baker Sports Medicine median Middle half National median
2019 $36 $1,176 $199–$4,249 $163
2020 $0 $708 $96–$2,890 $114
2021 $115 $1,213 $152–$3,994 $132
2022 $1,286 $1,230 $159–$3,998 $149
2023 $5,375 $584 $146–$2,836 $160
2024 $634 $628 $163–$3,168 $164
2025 $5,006 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CGG Medical Inc $9,161 16 payments
  2. Arthrex, Inc. $2,575 30 payments
  3. Abbott Laboratories $361 6 payments
  4. Smith+Nephew, Inc. $187 4 payments
  5. Stryker Corporation $47 2 payments
  6. MicroPort Orthopedics Inc $33 1 payment
  7. Next Science LLC $28 1 payment
  8. Paragon 28, Inc. $19 1 payment
  9. Vericel Corporation $15 1 payment
  10. Vertex Pharmaceuticals Incorporated $14 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,795 13 payments
  2. Food and Beverage $2,457 50 payments
  3. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. AMPLATZER AMULET $300 2 payments
  2. Bioinductive Implant with Arthroscopic Delivery System - Medium $93 1 payment
  3. ENDOBUTTON $69 1 payment
  4. MPO Medial Pivot Knee $33 1 payment
  5. PROCLAIM $31 2 payments
  6. SurgX $28 1 payment
  7. Xperience $28 1 payment
  8. BlastX $28 1 payment
  9. NA $24 1 payment
  10. MAKO $23 1 payment
  11. Other $115 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

248

Median for Sports Medicine: 144

Drug cost

$1,687

Median for Sports Medicine: $1,027

Branded share of claims

19.4%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 32 $636
Methylprednisolone Generic 51 $289
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $238
Meloxicam Generic 81 $218
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $189
Tramadol Hcl Generic 24 $80
Gabapentin Generic 12 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$93,813

Of which drugs: $19,780

Medicare patients

338

Average age 73

Services billed

11,163

188 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 70%
Diabetes 26%
Chronic kidney disease 25%
Ischemic heart disease 24%
Depression 17%
Atrial fibrillation 14%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 29 2,544 $17,769
Injection, methylprednisolone acetate, 1 mg J1010 Office 114 7,336 $734
Injection, methylprednisolone acetate, 40 mg J1030 Office 42 60 $177

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record